125 related articles for article (PubMed ID: 11567741)
21. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.
Verheul AF; Versteeg AA; De Reuver MJ; Jansze M; Snippe H
Infect Immun; 1989 Apr; 57(4):1078-83. PubMed ID: 2925240
[TBL] [Abstract][Full Text] [Related]
22. [SYNTHETIC CONJUGATED ANALOGUES OF CAPSULE POLYSACCHARIDES OF PNEUMOCOCCUS - AN INSTRUMENT FOR DETECTION OF POST-VACCINATION ANTIBODIES].
Kurbatova EA; Akhmatova EA; Akhmatova NK; Egorova NB; Yastrebova NE; Sukhova EV; Tsvetkov YE; Yashunsky DV; Nifantiev NE
Zh Mikrobiol Epidemiol Immunobiol; 2016 Nov; (6):54-60. PubMed ID: 30695390
[TBL] [Abstract][Full Text] [Related]
23. Polysaccharide-based pneumococcal vaccines in the prevention of acute otitis media.
Eskola J
Vaccine; 2000 Dec; 19 Suppl 1():S78-82. PubMed ID: 11163468
[TBL] [Abstract][Full Text] [Related]
24. Assessment of a commercial rapid urinary antigen test to detect Streptococcus pneumoniae in patients who received 23-valent pneumococcal polysaccharide vaccine.
Vázquez EG; Marcos MA; Vilella A; Yagüe J; Bayas JM; Mensa J
Eur J Clin Microbiol Infect Dis; 2004 Dec; 23(12):927-9. PubMed ID: 15599657
[No Abstract] [Full Text] [Related]
25. [Pneumococcal infections: Appraisal and perspectives in terms of adult vaccination].
Baratali L; Lang PO
Presse Med; 2015 Nov; 44(11):1155-61. PubMed ID: 26363530
[TBL] [Abstract][Full Text] [Related]
26. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
[TBL] [Abstract][Full Text] [Related]
27. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
[TBL] [Abstract][Full Text] [Related]
28. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide.
Csordas FC; Perciani CT; Darrieux M; Gonçalves VM; Cabrera-Crespo J; Takagi M; Sbrogio-Almeida ME; Leite LC; Tanizaki MM
Vaccine; 2008 Jun; 26(23):2925-9. PubMed ID: 18440673
[TBL] [Abstract][Full Text] [Related]
29. Pneumococcal otitis media and pneumococcal vaccines, a historical perspective.
Austrian R
Vaccine; 2000 Dec; 19 Suppl 1():S71-7. PubMed ID: 11163467
[TBL] [Abstract][Full Text] [Related]
30. Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm.
Wu D; Ji S; Hu T
Vaccine; 2013 Nov; 31(48):5623-6. PubMed ID: 24120485
[TBL] [Abstract][Full Text] [Related]
31. Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen.
Porro M; Costantino P; Viti S; Vannozzi F; Naggi A; Torri G
Mol Immunol; 1985 Aug; 22(8):907-19. PubMed ID: 4047043
[TBL] [Abstract][Full Text] [Related]
32. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.
Briles DE; Hollingshead SK; Nabors GS; Paton JC; Brooks-Walter A
Vaccine; 2000 Dec; 19 Suppl 1():S87-95. PubMed ID: 11163470
[TBL] [Abstract][Full Text] [Related]
33. Production, binding characteristics and protective immunity of monoclonal antibody to pneumococcal type-9V conjugate.
Lee CJ; Karpas A; Wang TR; Kosaka T; Koizumi K
Microbiol Immunol; 1996; 40(11):857-65. PubMed ID: 8985941
[TBL] [Abstract][Full Text] [Related]
34. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
Lin H; Peng Y; Lin Z; Zhang S; Guo Y
Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides.
Breukels MA; Zandvoort A; van Den Dobbelsteen GP; van Den Muijsenberg A; Lodewijk ME; Beurret M; Klok PA; Timens W; Rijkers GT
Infect Immun; 2001 Dec; 69(12):7583-7. PubMed ID: 11705936
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers.
Lee CJ; Wang TR; Frasch CE
Vaccine; 2001 Apr; 19(23-24):3216-25. PubMed ID: 11312018
[TBL] [Abstract][Full Text] [Related]
37. Complement dependency of splenic localization of pneumococcal polysaccharide and conjugate vaccines.
Breukels MA; Zandvoort A; Rijkers GT; Lodewijk ME; Klok PA; Harms G; Timens W
Scand J Immunol; 2005 Apr; 61(4):322-8. PubMed ID: 15853914
[TBL] [Abstract][Full Text] [Related]
38. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.
van Dam JE; Fleer A; Snippe H
Antonie Van Leeuwenhoek; 1990 Jun; 58(1):1-47. PubMed ID: 2195989
[No Abstract] [Full Text] [Related]
40. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.
Laferrière CA; Sood RK; de Muys JM; Michon F; Jennings HJ
Vaccine; 1997 Feb; 15(2):179-86. PubMed ID: 9066036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
